MX2019006066A - 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. - Google Patents

5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.

Info

Publication number
MX2019006066A
MX2019006066A MX2019006066A MX2019006066A MX2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A
Authority
MX
Mexico
Prior art keywords
thiazolidine
dione
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
MX2019006066A
Other languages
English (en)
Inventor
Pilar Pizcueta Lalanza Maria
Martinell Pedemonte Marc
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of MX2019006066A publication Critical patent/MX2019006066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se relaciona con un método para tratar o prevenir la enfermedad del hígado graso no alcohólico, la esteatohepatitis no alcohólica, un trastorno granulomatoso crónico, un síndrome de ovario poliquístico, un carcinoma de tiroides, un trastorno autoinmune de tiroides, un adenoma hipofisario, aterosclerosis, hipertensión, una enfermedad de la piel, una inflamación y una enfermedad autoinmune, y una enfermedad respiratoria inflamatoria mediante la administración de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3- tiazolidin-2,4-diona a un paciente que lo necesita. La descripción también se relaciona con 5-[[4-[2-[5-(1-hidroxietil)pi ridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para uso en una composición farmacéutica o en la fabricación de un medicamento para el tratamiento o la prevención de la enfermedad del hígado graso no alcohólico o la esteatohepatitis no alcohólica.
MX2019006066A 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. MX2019006066A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382584 2016-12-01
PCT/IB2017/057587 WO2018100557A1 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
MX2019006066A true MX2019006066A (es) 2019-09-10

Family

ID=57517838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006066A MX2019006066A (es) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.

Country Status (20)

Country Link
US (1) US11938122B2 (es)
EP (1) EP3548026B1 (es)
JP (1) JP7040798B2 (es)
KR (1) KR102595034B1 (es)
CN (1) CN110022877B (es)
AU (1) AU2017370003B2 (es)
BR (1) BR112019011334A2 (es)
CA (1) CA3044364A1 (es)
CY (1) CY1124116T1 (es)
DK (1) DK3548026T3 (es)
EA (1) EA201991304A1 (es)
ES (1) ES2867300T3 (es)
HR (1) HRP20210576T1 (es)
HU (1) HUE054346T2 (es)
LT (1) LT3548026T (es)
MX (1) MX2019006066A (es)
PL (1) PL3548026T3 (es)
PT (1) PT3548026T (es)
SI (1) SI3548026T1 (es)
WO (1) WO2018100557A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3548026T3 (pl) 2016-12-01 2021-08-23 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion do leczenia niealkoholowej stłuszczeniowej choroby wątroby
JP7376934B2 (ja) 2018-06-06 2023-11-09 ミノリックス セラピューティクス エセ．エレ． ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩
EP4142720A1 (en) * 2020-04-30 2023-03-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202352T1 (de) * 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
EP1465627B1 (en) 2001-12-21 2006-03-08 SmithKline Beecham Corporation DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
MX2008011871A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
EA035866B1 (ru) * 2014-04-02 2020-08-21 Минорикс Терапьютикс С.Л. Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных
PL3548026T3 (pl) 2016-12-01 2021-08-23 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion do leczenia niealkoholowej stłuszczeniowej choroby wątroby

Also Published As

Publication number Publication date
JP7040798B2 (ja) 2022-03-23
PL3548026T3 (pl) 2021-08-23
DK3548026T3 (da) 2021-04-19
HUE054346T2 (hu) 2021-08-30
BR112019011334A2 (pt) 2019-10-15
PT3548026T (pt) 2021-04-22
AU2017370003A1 (en) 2019-06-06
AU2017370003B2 (en) 2023-04-13
EP3548026A1 (en) 2019-10-09
LT3548026T (lt) 2021-05-25
CA3044364A1 (en) 2018-06-07
WO2018100557A1 (en) 2018-06-07
CN110022877B (zh) 2023-06-23
US20200093812A1 (en) 2020-03-26
JP2020500868A (ja) 2020-01-16
EP3548026B1 (en) 2021-01-20
EA201991304A1 (ru) 2019-12-30
KR102595034B1 (ko) 2023-10-26
KR20190086766A (ko) 2019-07-23
HRP20210576T1 (hr) 2021-05-28
SI3548026T1 (sl) 2021-07-30
US11938122B2 (en) 2024-03-26
ES2867300T3 (es) 2021-10-20
CY1124116T1 (el) 2022-05-27
CN110022877A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
MX2019006066A (es) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
PH12019500056A1 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
IN2013MU01468A (es)
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
PE20142292A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
NZ602125A (en) Uses of dgat1 inhibitors
MX2013009842A (es) Composicion que comprende receptor gamma activado por proliferador de peroxisoma.
MX2020013182A (es) Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
BR112015010121A2 (pt) inibidores de quinase de tirosina de bruton
MY184876A (en) Pharmaceutical composition for preventing cccdna formation of hepatitis b virus
MX2022013021A (es) Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
NZ610289A (en) Oxazolo[5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
MX2018006921A (es) Métodos y composiciones para el tratamiento de úlceras gástricas.
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
EA201692515A1 (ru) Новая фармацевтическая композиция на основе софосбувира и рибавирина
Aydin Peginterferon-α-2b
MX2016002856A (es) Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon.
PH12014501088A1 (en) Pharmaceutical composition for preventing or treating hyperlipidemia
Novoa Vasculitis and panniculitis: 3 case reports